Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Bought by Nordea Investment Management AB

Nordea Investment Management AB grew its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 4.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 279,714 shares of the company’s stock after purchasing an additional 12,851 shares during the quarter. Nordea Investment Management AB owned approximately 0.58% of Amphastar Pharmaceuticals worth $10,386,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of AMPH. Victory Capital Management Inc. lifted its holdings in Amphastar Pharmaceuticals by 10.9% during the 3rd quarter. Victory Capital Management Inc. now owns 218,531 shares of the company’s stock worth $10,605,000 after buying an additional 21,530 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter worth about $11,070,000. Wellington Management Group LLP purchased a new stake in Amphastar Pharmaceuticals during the third quarter worth approximately $957,000. Intech Investment Management LLC acquired a new position in Amphastar Pharmaceuticals in the second quarter valued at approximately $426,000. Finally, XTX Topco Ltd purchased a new position in Amphastar Pharmaceuticals in the third quarter valued at approximately $674,000. 65.09% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $36.63 on Thursday. The company’s 50 day simple moving average is $43.31 and its 200-day simple moving average is $44.28. The firm has a market cap of $1.76 billion, a PE ratio of 12.21, a price-to-earnings-growth ratio of 0.87 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 12-month low of $34.69 and a 12-month high of $58.64. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, EVP Yakob Liawatidewi sold 5,214 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the sale, the executive vice president now directly owns 74,938 shares of the company’s stock, valued at $3,900,522.90. This represents a 6.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard K. Prins sold 5,000 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $48.80, for a total value of $244,000.00. Following the sale, the director now directly owns 31,471 shares of the company’s stock, valued at $1,535,784.80. The trade was a 13.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 41,533 shares of company stock worth $1,987,482 in the last 90 days. Company insiders own 27.10% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on AMPH shares. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target for the company. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $60.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.